The Clock Is Running Out on These Denials

Every quarter CMS activates new HCPCS codes. Most practices update their billing systems, start submitting claims and move on. What almost nobody tracks is what happens in the 60 to 90 days after a new code activates, before the commercial payers update their fee schedule systems to recognize it. That window is where a significant population of recoverable revenue simply dies.

How the lag works

When CMS activates a new J-code, the clinical policy systems at major commercial payers update relatively quickly. Coverage criteria get added. Formulary entries get made. Utilization management platforms recognize the new drug and start approving authorizations.

The fee schedule system is different. It runs on its own update cycle: quarterly batch processing, manual entry, a separate team and a separate timeline. It does not coordinate with the clinical policy update.

During the gap between those two updates, every claim submitted on the new code hits an empty pricing field in the payer’s adjudication system. The algorithm has no price to apply, so it returns a denial: CO-96, paired with N448 or N386 depending on the payer.

CO-96 reads as a non-covered charge. It looks like a coverage determination. It is not. It is a pricing table gap formatted as a coverage denial. If the practice argues coverage, the appeal loses, the claim sits and the revenue disappears.

What got hit this quarter

These codes activated in Q2 and Q3 2026. Each one created a lag window, and most have a specific denial trap beyond the standard fee schedule gap. Scan for any code your practice billed this year.

What each one means and what to do about it

J9277: Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), 1 mg subcutaneous

Merck’s subcutaneous formulation of pembrolizumab. The trap here is not just fee schedule lag. Payer adjudication systems are confusing J9277 with the established IV code J9271 and generating instant crosswalk rejections. The system sees pembrolizumab, finds J9271 already in its formulary and treats J9277 as a duplicate or invalid alternate code. Claims come back denied before the fee schedule question is even reached.

Practices that switched patients from IV to subcutaneous and billed J9277 are seeing denials that look like duplicate billing errors. They are crosswalk failures on a code the system does not yet have a dedicated entry for.

What to check: Any J9277 claim denied CO-96 or with a duplicate claim remark. Pull the authorization record. If the authorization was issued under the subcutaneous indication and the denial references the IV code or flags duplicate billing, the crosswalk failure is documentable.

J9278: Carboplatin Avyxa (Kyxata), 1 mg

A manufacturer-specific platinum compound code. Payer fee schedule systems are defaulting to generic carboplatin billing guidelines and denying J9278 as having no active fee schedule entry. This is a straightforward fee schedule lag denial: CO-96 with N448, while the administration lines on the same claim pay at CO-45. The contradiction is on the face of the EOB.

What to check: Any J9278 claim denied CO-96 from April through June 2026. The lag window at most major payers has likely closed or is closing now. Claims still within timely filing are recoverable.

J9601: Lynozyfic (linvoseltamab-gcpt), 1 mg

Regeneron’s multiple myeloma bispecific. This code replaced the temporary C9307 and unclassified J9999 codes on April 1, and two problems are running at once. First, standard fee schedule lag: every claim in the activation window hit an empty pricing field and generated CO-96.

Second, and more operationally dangerous, the drug has a step-up dosing protocol with very different unit counts. Step-up doses are billed at 5 units; full therapeutic doses at 200. Payer systems without the step-up protocol loaded are auto-denying step-up claims as underdosed or clinically inconsistent. The dosing is correct. The payer system doesn’t recognize the protocol.

What to check: J9601 denials from April 2026 forward. Separate step-up claims from full-dose claims. Fee schedule lag applies to both; step-up denials need a different argument that documents the FDA-approved dosing schedule against the payer’s own authorization criteria.

J9003: Camcevi ETM (leuprolide injectable), 1 mg

Completely distinct from the older leuprolide codes J1952 and J1950. Automated systems cross-reference patient history and flag J9003 as duplicate therapy when earlier leuprolide administration appears under a different code. This is not fee schedule lag; it is a formulary crosswalk failure combined with a patient history comparison error. Prior administration under J1952 or J1950 is not duplicate therapy for a distinct formulation with its own HCPCS code.

What to check: J9003 claims denied as duplicate therapy or CO-22 where the patient has prior leuprolide history under J1952 or J1950. If the authorization recognized J9003 as a distinct drug, the claims system cannot apply duplicate therapy logic against a separately authorized treatment.

J8502: Aponvie (aprepitant injection), 1 mg

An antiemetic injection generating silent contractual write-offs rather than hard denials, because authorization systems fail to map the outpatient post-operative administration rules. Claims pay at the wrong rate or get bundled into the surgical or infusion encounter instead of paying as separate lines. This is an underpayment population, not a denial population.

What to check: J8502 claims from April 2026 forward where the drug line paid at zero or was bundled into the facility or infusion fee. If the contract requires independent payment on drug lines, a bundled zero-dollar drug line is an underpayment, not a denial.

J9053: Blenrep (belantamab mafodotin-blmf), 0.1 mg

The unit matters enormously: J9053 is billed at 0.1 mg per unit, so a standard weight-based dose runs into the hundreds of units. A single clerical error in the unit calculation produces a claim that looks implausible to an automated system, which denies it without human review. The code also replaced unclassified J9999 and J3590 billing, which creates its own fee schedule lag window. Every J9053 claim submitted in July and August 2026 to a major commercial payer is at elevated risk of CO-96. This window is active right now.

What to check: Any J9053 denial from July 2026 forward. Verify the unit count at 0.1 mg per unit against the patient’s weight-based dose, then check the EOB for CO-45 on the administration lines against CO-96 on the drug line. Both problems can be on the same claim.

J9062: Rybrevant Faspro (amivantamab and hyaluronidase), 5 mg subcutaneous

Separate from the IV code J9061. Authorizations for amivantamab were issued under J9061. When practices moved patients to the subcutaneous formulation and billed J9062, claims came back denied as authorization absent: the authorization record shows J9061, the claim shows J9062, and the system finds no match. Same drug, same patient, same therapeutic agent. If the UM vendor authorized amivantamab for this patient, the claims system cannot deny the subcutaneous formulation as unauthorized without the two determinations contradicting each other. This window is also active right now.

What to check: Any J9062 denial from July 2026 forward coded as authorization absent or CO-96. Pull the J9061 authorization record. If amivantamab was authorized under the IV code and the denial rests only on the missing J9062-specific authorization, the contradiction is documentable.

J9232: Docetaxel Hospira (Pfizer), 1 mg

CMS was explicit that J9232 is not therapeutically equivalent to J9171. Practices that administered the Hospira product and billed J9171 are seeing payments recouped on audit, because the billed code doesn’t match the product. Practices that billed J9232 correctly are getting CO-96 lag denials, because the code only activated July 1. Billing the wrong code generates a recoupment; billing the right code generates a denial. Both are recoverable, with different arguments.

What to check: J9171 claims from July 2026 forward where the product was Hospira docetaxel: match the NDC to the product administered. J9232 denials from July 2026 forward are fee schedule lag denials, recoverable on the standard CO-45 contradiction.

The contradiction that reverses fee schedule lag denials

The argument is the same whichever code generated the CO-96. On every fee schedule lag denial, the drug line carries CO-96 at zero dollars, while the administration lines on the same claim carry CO-45 and pay at the contracted rate.

CO-45 is a contracted rate reduction. It applies only where an established contracted fee schedule exists between payer and provider. A payer that applies CO-45 to the administration of a drug while asserting that same drug has no fee schedule entry has issued two mutually exclusive determinations on the same claim and date. The administration paying is the payer’s own confirmation that the service occurred. The drug line denial is a pricing system error. Both facts are on the same EOB, and the argument needs no new clinical documentation and no physician reviewer.

Why the window matters

Most commercial payer contracts set timely filing at 12 months from the date of service, and some set appeal deadlines at 180 days from the initial denial. On the 180-day calendar, CO-96 denials on Q2 2026 dates of service are at or near their deadline now, in September 2026. Q3 activations have more runway, but the lag windows on J9053 and J9062 are still generating new denials while earlier ones age toward their deadlines.

Once timely filing closes, the argument doesn’t get harder. It disappears. A recoverable claim with a documented contradiction becomes an unrecoverable write-off because the clock ran out.

What to do right now

1. Pull a denial report for the codes above, dates of service from April 2026 forward, filtered to CO-96 with N448 or N386.

2. For each claim, pull the full EOB and check whether the administration lines paid at CO-45. If they did, the contradiction is documented and the claim is recoverable.

3. Handle J9003 duplicate therapy denials and J9062 authorization absent denials with the code-specific arguments above.

4. For J8502, audit paid claims, not denied ones. The underpayment is in the claims that cleared.

If you want a second set of eyes on what’s in your denial stack before the deadline hits, send us a message.